ABSTRACT
Pancreatic cancer is highly metastatic and has a poor prognosis. However, there is no established treatment for pancreatic cancer. Lysophosphatidic acid (LPA) has been shown to be present in effluents of cancers and involved in migration and proliferation in a variety of cancer cells, including pancreatic cancer cells, in vitro. In the current study, we examined whether an orally active LPA antagonist is effective for pancreatic cancer tumorigenesis and metastasis in vivo. Oral administration of Ki16198, which is effective for LPA(1) and LPA(3), into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. Ki16198 inhibited LPA-induced migration and invasion in several pancreatic cancer cells in vitro, which was associated with the inhibition of LPA-induced MMP production. In conclusion, Ki16198 is a promising orally active LPA antagonist for inhibiting the invasion and metastasis of pancreatic cancer cells. The inhibitory effects of the antagonist on invasion and metastasis in vivo may be partially explained by the inhibition of motility activity and MMP production in cancer cells.
Subject(s)
Isoxazoles/pharmacology , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Propionates/pharmacology , Receptors, Lysophosphatidic Acid/antagonists & inhibitors , Animals , Ascites/metabolism , Cell Line, Tumor , Cell Movement/drug effects , Humans , Isoxazoles/administration & dosage , Isoxazoles/therapeutic use , Lysophospholipids/pharmacology , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Invasiveness , Neoplasm Metastasis/drug therapy , Pancreatic Neoplasms/metabolism , Peritoneal Neoplasms/pathology , Peritoneal Neoplasms/prevention & control , Peritoneal Neoplasms/secondary , Propionates/administration & dosage , Propionates/therapeutic use , Xenograft Model Antitumor AssaysABSTRACT
AIMS: We investigated the mechanisms of action of lysophosphatidic acid (LPA) to regulate vascular endothelial (VE)-cadherin dynamics and cell-cell contact. METHODS AND RESULTS: While a low concentration of LPA stimulated VE-cadherin internalization and subsequent cell-cell dissociation, a high concentration of LPA masked the disruptive actions on VE-cadherin and protected the barrier function in human vascular endothelial cells. Knockdown experiments of major LPA receptor subtypes, i.e. LPA(1) and p2y5 (also termed LPA(6)), with their specific small interfering RNAs, showed that LPA(1) and LPA(6) mediate the LPA-induced disruptive and protective actions on barrier integrity, respectively. LPA(6)-mediated tube formation, reflecting stabilization of barrier integrity, was confirmed by in vitro angiogenesis assay. The LPA(1)-mediated disruptive actions were inhibited by pertussis toxin, dominant-negative Rac1, and inhibitors for c-Jun NH(2)-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38MAPK), but not by dominant-negative RhoA. In contrast, the LPA(6)-mediated protective actions were associated with activation of Src and Rap1 and attenuated by abrogation of their activities. Further characterization showed that Rap1 is located downstream of Src and dependent on C3G, a Rap1 guanine nucleotide exchange factor. Finally, an LPA antagonist significantly inhibited lactic acid-induced limb lesions in vivo, which may be attributed to dysfunction of endothelial cells. CONCLUSION: LPA induced disruption and protection of VE-cadherin integrity through LPA(1)-G(i) protein-Rac1-JNK/p38MAPK and LPA(6)-G(12/13) protein-Src-C3G-Rap1 pathways, respectively.
Subject(s)
Antigens, CD/metabolism , Cadherins/metabolism , GTP-Binding Protein alpha Subunits, G12-G13/physiology , GTPase-Activating Proteins/physiology , Receptors, Lysophosphatidic Acid/physiology , Receptors, Purinergic P2/physiology , src-Family Kinases/physiology , Animals , Cells, Cultured , Humans , Lysophospholipids/pharmacology , MAP Kinase Kinase 4/physiology , Male , Protein Transport , Rats , Rats, Wistar , p38 Mitogen-Activated Protein Kinases/physiologyABSTRACT
Low-density lipoprotein (LDL) and lysophosphatidic acid (LPA), one of the lipid components of lipoprotein, induced the DNA synthesis of coronary artery smooth muscle cells (CASMCs). The LDL- and LPA-induced DNA synthesis was markedly inhibited by the LPA receptor antagonist Ki16425, pertussis toxin, small interfering RNAs targeted for LPA1 receptors, and a potent calcineurin inhibitor cyclosporine A. It has been reported that LDL and LPA induced a migration response in a manner sensitive to Ki16425, pertussis toxin, and a LPA1 receptor-specific small interfering RNA. However, cyclosporine A was ineffective in inhibiting the migration response. Instead, an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor markedly suppressed the migration response to LDL and LPA without having any significant effect on DNA synthesis. Thus, the LDL-induced stimulation of DNA synthesis and migration in CASMCs is mediated by its component LPA through LPA1 receptors and G(i/o)-proteins. Ca2+/calcineurin pathways and transactivation of EGF receptors mediate LPA1-receptor-induced DNA synthesis and migration, respectively.
Subject(s)
Cell Movement/physiology , Coronary Vessels/metabolism , Coronary Vessels/physiology , DNA/biosynthesis , Lipoproteins, LDL/physiology , Lysophospholipids/physiology , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/physiology , Signal Transduction/physiology , Calcineurin/physiology , Cells, Cultured , ErbB Receptors/physiology , Humans , Receptors, Lysophosphatidic Acid/agonists , Transcriptional Activation/physiologyABSTRACT
Malignant ascites from pancreatic cancer patients has been reported to stimulate migration of pancreatic cancer cells through lysophosphatidic acid (LPA) and LPA(1) receptors. Indeed, ascites- and LPA-induced migration was inhibited by Ki16425, an LPA(1) and LPA(3) antagonist, in Panc-1 cells. Unexpectedly, however, in the presence of Ki16425, ascites and LPA inhibited cell migration in response to epidermal growth factor (EGF). The inhibitory migratory response to ascites and LPA was also observed in the cells treated with pertussis toxin (PTX), a G(i) protein inhibitor, and attenuated by a small interfering RNA (siRNA) specific to the LPA(2) receptor. The inhibitory LPA action was reversed by the regulators of G-protein signaling domain of p115RhoGEF, dominant-negative RhoA or C3 toxin. Indeed, LPA activated RhoA, which was attenuated by the siRNA against the LPA(2) receptor. Moreover, LP-105, an LPA(2) agonist, also inhibited EGF-induced migration in the PTX-treated cells. A similar inhibitory migration response through LPA(2) receptors was also observed in YAPC-PD, BxPC-3, CFPAC-1 and PK-1 pancreatic cancer cell lines. LPA also inhibited the invasion of Panc-1 cells in the PTX-treated cells in the in vitro Matrigel invasion assay. We conclude that LPA(2) receptors are coupled to the G(12/13) protein/Rho-signaling pathway, leading to the inhibition of EGF-induced migration and invasion of pancreatic cancer cells.
Subject(s)
Ascites/metabolism , Cell Movement/drug effects , Lysophospholipids/pharmacology , Pancreatic Neoplasms/metabolism , Receptors, Lysophosphatidic Acid/physiology , Ascites/pathology , Cell Line, Tumor , Collagen , Drug Combinations , Epidermal Growth Factor/pharmacology , GTP-Binding Protein alpha Subunits, Gi-Go/antagonists & inhibitors , Humans , Isoxazoles/pharmacology , Laminin , Neoplasm Invasiveness , Pancreatic Neoplasms/pathology , Pertussis Toxin/pharmacology , Propionates/pharmacology , Proteoglycans , RNA, Small Interfering/genetics , Receptors, Lysophosphatidic Acid/agonists , Receptors, Lysophosphatidic Acid/antagonists & inhibitors , Receptors, Lysophosphatidic Acid/genetics , rhoA GTP-Binding Protein/metabolismABSTRACT
A 76-year-old woman underwent a total gastrectomy with dissection of second group of lymph nodes for type 2 gastric cancer at the back wall of the middle stomach body. The gastric cancer was moderately differentiated adenocarcinoma, which involved the second group of lymph nodes. Tumor makers increased-the CEA level became 10.7 ng/mL and the CA19-9 level became 110 U/mL after the operation. CT scan showed a solitary splenic tumor sized about 60 mm in diameter. No other prominent metastatic lesions were demonstrated, so that a splenectomy was performed in February 2008. Histopathologically the splenic tumor was adenocarcinoma, and was diagnosed as metastasis of gastric cancer. The report which excised asynchronism spleen metastasis of a stomach cancer after the operation is very rare. She remains recurrence free 4 months later.
Subject(s)
Splenic Neoplasms/secondary , Stomach Neoplasms/pathology , Aged , Biomarkers, Tumor/blood , Female , Gastrectomy , Humans , Remission Induction , Splenic Neoplasms/blood , Splenic Neoplasms/diagnostic imaging , Splenic Neoplasms/surgery , Stomach Neoplasms/blood , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/surgery , Tomography, X-Ray ComputedABSTRACT
While inflammatory cytokines are well-recognized critical factors for the induction of cyclooxygenase-2 (COX-2) in activated fibroblast-like synovial cells, the roles of biologically active components other than inflammatory cytokines in synovial fluid remain unknown. Herein, we assessed the role of lysophosphatidic acid (LPA), a pleiotropic lipid mediator, in COX-2 induction using synovial fluid of patients with rheumatoid arthritis (RA) in fibroblast-like RA synovial cells. Synovial fluid from RA patients stimulated COX-2 induction, which was associated with prostaglandin E(2) production, in RA synovial cells. The synovial fluid-induced actions were inhibited by G(i/o) protein inhibitor pertussis toxin and LPA receptor antagonist 3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid (Ki16425). In fact, LPA alone significantly induced COX-2 expression and enhanced IL-1alpha- or IL-1beta-induced enzyme expression in a manner sensitive to pertussis toxin and Ki16425. RA synovial cells abundantly expressed LPA(1) receptor compared with other LPA receptor subtypes. Moreover, synovial fluid contains a significant amount of LPA, an LPA-synthesizing enzyme autotaxin, and its substrate lysophosphatidylcholine. In conclusion, LPA existing in synovial fluid plays a critical role in COX-2 induction in collaboration with inflammatory cytokines in RA synovial cells. Ki16425-sensitive LPA receptors may be therapeutic targets for RA.
Subject(s)
Adjuvants, Immunologic/physiology , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , Cyclooxygenase 2/biosynthesis , Fibroblasts/metabolism , Lysophospholipids/physiology , Synovial Fluid/enzymology , Synovial Fluid/immunology , Adjuvants, Immunologic/metabolism , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/enzymology , Cell Line, Tumor , Cytokines/physiology , Dinoprostone/biosynthesis , Dinoprostone/physiology , Enzyme Induction/immunology , Fibroblasts/enzymology , Fibroblasts/pathology , Humans , Inflammation Mediators/metabolism , Inflammation Mediators/physiology , Isoxazoles/pharmacology , Isoxazoles/therapeutic use , Lysophospholipids/metabolism , Propionates/pharmacology , Propionates/therapeutic use , Receptors, Lysophosphatidic Acid/antagonists & inhibitors , Synovial Fluid/cytologyABSTRACT
The migration of vascular smooth muscle cells (SMCs) is a hallmark of the pathogenesis of atherosclerosis and restenosis after angioplasty. Plasma low-density lipoprotein (LDL), but not high-density lipoprotein (HDL), induced the migration of human coronary artery SMCs (CASMCs). Among bioactive lipids postulated to be present in LDL, lysophosphatidic acid (LPA) appreciably mimicked the LDL action. In fact, the LDL-induced migration was markedly inhibited by pertussis toxin, an LPA receptor antagonist Ki-16425, and a small interfering RNA (siRNA) targeted for LPA(1) receptors. Moreover, LDL contains a higher amount of LPA than HDL does. HDL markedly inhibited LPA- and platelet-derived growth factor (PDGF)-induced migration, and sphingosine 1-phosphate (S1P), the content of which is about fourfold higher in HDL than in LDL, mimicked the HDL action. The inhibitory actions of HDL and S1P were suppressed by S1P(2) receptor-specific siRNA. On the other hand, the degradation of the LPA component of LDL by monoglyceride lipase or the antagonism of LPA receptors by Ki-16425 allowed LDL to inhibit the PDGF-induced migration. The inhibitory effect of LDL was again suppressed by S1P(2) receptor-specific siRNA. In conclusion, LPA/LPA(1) receptors and S1P/S1P(2) receptors mediate the stimulatory and inhibitory migration response to LDL and HDL, respectively. The balance of not only the content of LPA and S1P in lipoproteins but also the signaling activity between LPA(1) and S1P(2) receptors in the cells may be critical in determining whether the lipoprotein is a positive or negative regulator of CASMC migration.
Subject(s)
Coronary Vessels/physiology , Lipoproteins/metabolism , Lysophospholipids/metabolism , Muscle, Smooth, Vascular/physiology , Myocytes, Smooth Muscle/physiology , Adult , Cell Movement/physiology , Cells, Cultured , Humans , Male , Middle AgedABSTRACT
Hepatic arterial infusion (HAI) chemotherapy is one of the strategies for cases in poor performance status. This is a case report of multiple liver metastases from rectal cancer in poor performance status successfully treated with HAI plus CPT-11. A 59-year-old man who had rectal cancer, multiple liver metastases and para-aortic LN metastasis underwent a laparoscopic rectal anterior resection. He denied receiving postoperative chemotherapy and selected alternative therapy at another clinic. Four months later, he visited our hospital. His liver metastasis and performance status got worse, so HAI of 5-FU 1250 mg/m2 for 5-hour weekly (weekly high-dose 5-FU: WHF) was started at first. After 3 courses, his status improved, so systemic chemotherapy was added. HAI (WHF: 1000 mg/m2) plus CPT-11 (100 mg/m2) was effective, and liver metastases showed a significant reduction (PR) on abdominal CT. HAI plus CPT-11 was effective for a patient of the poor performance status with unresectable liver metastasis.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/analogs & derivatives , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Biomarkers, Tumor/blood , Camptothecin/administration & dosage , Camptothecin/therapeutic use , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Humans , Infusions, Intra-Arterial , Irinotecan , Liver Neoplasms/blood , Liver Neoplasms/pathology , Male , Middle Aged , Rectal Neoplasms/blood , Rectal Neoplasms/surgery , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Lysophosphatidic acid (LPA) is a lipid mediator with multiple biological activities that may affect the progression of various cancers. Malignant ascites contains high levels of LPA as well as vascular endothelial growth factor (VEGF). Although LPA receptors are widely expressed in normal as well as cancer cells, little is known about the effect of LPA on host cells. Therefore, we evaluated the effect of LPA specifically on peritoneal mesothelial cells (PMC), and assessed another aspect of LPA in tumor biology mediated through the host cells. MATERIALS AND METHODS: The effect of LPA on the production of VEGF was evaluated by ELISA and northern blotting. Next, we quantified human- and mouse-VEGF separately in ascitic fluid of nude mice inoculated intraperitoneally with a human gastric cancer, MKN45, and thus evaluated the ratio of host-derived VEGF in malignant ascites. RESULTS: Addition of 10 to 80 mum LPA enhanced VEGF production by PMC through gene activation. The effect was strongly inhibited by pre-treatment with PTX or Ki16425, indicating that the effect was mainly dependent on the LPA1 signal. Of the VEGF in ascitic fluid at 3 weeks after tumor inoculation, 12.8% was derived from mouse cells. At 6 weeks, however, the ratio of host-derived VEGF was reduced to 5.0%, suggesting that the ratio of host-derived VEGF may be higher in the earlier phase. CONCLUSION: Because tumor growth is often associated with an increase of LPA concentration in ascites, stimulation of VEGF production in PMC might have an important role in the growth of cancer cells disseminated in the peritoneal cavity.
Subject(s)
Ascites/metabolism , Lysophospholipids/metabolism , Lysophospholipids/pharmacology , Stomach Neoplasms/physiopathology , Vascular Endothelial Growth Factor A/genetics , Animals , Cell Line, Tumor , Culture Media, Conditioned/pharmacology , Disease Models, Animal , Epithelial Cells/physiology , Epithelium/physiology , Female , Humans , Isoxazoles/pharmacology , Mice , Mice, Inbred BALB C , Mice, Nude , Pertussis Toxin/pharmacology , Propionates/pharmacology , RNA, Messenger/analysis , Receptors, Lysophosphatidic Acid/geneticsABSTRACT
Lysophosphatidic acid (LPA), which interacts with at least three G protein-coupled receptors (GPCRs), LPA1/Edg-2, LPA2/Edg-4, and LPA3/Edg-7, is a lipid mediator with diverse effects on various cells. Here, we investigated the expression profiles of LPA receptors and patterns of LPA-induced migration in gastric cancer cells. Northern blot analysis revealed that various gastric cancer cells expressed variable levels of LPA1, LPA2, and LPA3 without a consistent pattern. Using a Boyden chamber assay, LPA markedly increased cell migration of LPA1-expressing cells, the effects of which were almost totally abrogated by Ki16425, an LPA antagonist against LPA1 and LPA3. In contrast, LPA by itself did not significantly induce migration in MKN28 and MKN74 cells, which exclusively expressed LPA2. However, when hepatocyte growth factor (HGF) was placed with LPA in the lower chamber, LPA induced migration of these cells in a dose-dependent manner. Immunoprecipitation analysis revealed that LPA induced transient tyrosine phosphorylation of c-Met in LPA2-expressing cells, which suggests that the transactivation of c-Met by LPA causes a cooperative migratory response with HGF to these cells. Our results indicate that LPA regulates the migration of gastric cancer cells in a receptor-specific manner and suggest that the expression pattern of LPA receptors may affect the metastatic behavior of gastric cancer.
Subject(s)
Chemotaxis/drug effects , Lysophospholipids/pharmacology , Stomach Neoplasms/pathology , Gene Expression Profiling , Hepatocyte Growth Factor/pharmacology , Humans , Phosphorylation , Proto-Oncogene Proteins c-met/metabolism , RNA, Messenger/analysis , Receptors, G-Protein-Coupled/genetics , Receptors, Lysophosphatidic Acid/geneticsABSTRACT
Autotaxin (ATX) is a tumor cell motility-stimulating factor originally isolated from melanoma cell supernatant that has been implicated in regulation of invasive and metastatic properties of cancer cells. Recently, we showed that ATX is identical to lysophospholipase D, which converts lysophosphatidylcholine to a potent bioactive phospholipid mediator, lysophosphatidic acid (LPA), raising the possibility that autocrine or paracrine production of LPA by ATX contributes to tumor cell motility. Here we demonstrate that LPA and ATX mediate cell motility-stimulating activity through the LPA receptor, LPA(1). In fibroblasts isolated from lpa(1)(-/-) mice, but not from wild-type or lpa(2)(-/-), cell motility stimulated with LPA and ATX was completely absent. In the lpa(1)(-/-) cells, LPA-stimulated lamellipodia formation was markedly diminished with a concomitant decrease in Rac1 activation. LPA stimulated the motility of multiple human cancer cell lines expressing LPA(1), and the motility was attenuated by an LPA(1)-selective antagonist, Ki16425. The present study suggests that ATX and LPA(1) represent potential targets for cancer therapy.
Subject(s)
Glucose-6-Phosphate Isomerase/physiology , Glycoproteins/physiology , Lysophospholipids/metabolism , Lysophospholipids/physiology , Multienzyme Complexes/physiology , Animals , Calcium/metabolism , Cell Line , Cell Line, Tumor , Cell Movement , Cells, Cultured , Chemotaxis , Dose-Response Relationship, Drug , Fibroblasts/metabolism , Isoxazoles/pharmacology , Mice , Mice, Knockout , Mice, Transgenic , Microscopy, Fluorescence , Models, Biological , Neoplasms/metabolism , Phosphodiesterase I , Phosphoric Diester Hydrolases/metabolism , Platelet-Derived Growth Factor/pharmacology , Propionates/pharmacology , Pyrophosphatases , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Skin/cytology , Time Factors , rac1 GTP-Binding Protein/metabolism , rhoA GTP-Binding Protein/metabolismABSTRACT
Cytokines and growth factors in malignant ascites are thought to modulate a variety of cellular activities of cancer cells and normal host cells. The motility of cancer cells is an especially important activity for invasion and metastasis. Here, we examined the components in ascites, which are responsible for cell motility, from patients and cancer cell-injected mice. Ascites remarkably stimulated the migration of pancreatic cancer cells. This response was inhibited or abolished by pertussis toxin, monoglyceride lipase, an enzyme hydrolyzing lysophosphatidic acid (LPA), and Ki16425 and VPC12249, antagonists for LPA receptors (LPA1 and LPA3), but not by an LPA3-selective antagonist. These agents also inhibited the response to LPA but not to the epidermal growth factor. In malignant ascites, LPA is present at a high level, which can explain the migration activity, and the fractionation study of ascites by lipid extraction and subsequent thin-layer chromatography indicated LPA as an active component. A significant level of LPA1 receptor mRNA is expressed in pancreatic cancer cells with high migration activity to ascites but not in cells with low migration activity. Small interfering RNA against LPA1 receptors specifically inhibited the receptor mRNA expression and abolished the migration response to ascites. These results suggest that LPA is a critical component of ascites for the motility of pancreatic cancer cells and LPA1 receptors may mediate this activity. LPA receptor antagonists including Ki16425 are potential therapeutic drugs against the migration and invasion of cancer cells.
Subject(s)
Ascites/metabolism , Lysophospholipids/metabolism , Pancreatic Neoplasms/metabolism , Receptors, G-Protein-Coupled/metabolism , Adult , Animals , Blotting, Northern , Cell Adhesion , Cell Division , Cell Line, Tumor , Cell Movement , Chromatography, Thin Layer , Dose-Response Relationship, Drug , Epidermal Growth Factor/metabolism , Female , Humans , Isoxazoles/pharmacology , Lipids , Male , Mice , Mice, Inbred BALB C , Middle Aged , Monoacylglycerol Lipases/pharmacology , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Transplantation , Pertussis Toxin/pharmacology , Propionates/pharmacology , RNA, Messenger/metabolism , Receptors, Lysophosphatidic Acid , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , TransfectionABSTRACT
Lysophosphatidic acid (LPA) exerts a variety of biological responses through specific receptors: three subtypes of the EDG-family receptors, LPA1, LPA2, and LPA3 (formerly known as EDG-2, EDG-4, and EDG-7, respectively), and LPA4/GPR23, structurally distinct from the EDG-family receptors, have so far been identified. In the present study, we characterized the action mechanisms of 3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid (Ki16425) on the EDG-family LPA receptors. Ki16425 inhibited several responses specific to LPA, depending on the cell types, without any appreciable effect on the responses to other related lipid receptor agonists, including sphingosine 1-phosphate. With the cells overexpressing LPA1, LPA2, or LPA3, we examined the selectivity and mode of inhibition by Ki16425 against the LPA-induced actions and compared them with those of dioctyl glycerol pyrophosphate (DGPP 8:0), a recently identified antagonist for LPA receptors. Ki16425 inhibited the LPA-induced response in the decreasing order of LPA1 >/= LPA3 >> LPA2, whereas DGPP 8:0 preferentially inhibited the LPA3-induced actions. Ki16425 inhibited LPA-induced guanosine 5'-O-(3-thio)triphosphate binding as well as LPA receptor binding to membrane fractions with a same pharmacological specificity as in intact cells. The difference in the inhibition profile of Ki16425 and DGPP 8:0 was exploited for the evaluation of receptor subtypes involved in responses to LPA in A431 cells. Finally, Ki16425 also inhibited LPA-induced long-term responses, including DNA synthesis and cell migration. In conclusion, Ki16425 selectively inhibits LPA receptor-mediated actions, especially through LPA1 and LPA3; therefore, it may be useful in evaluating the role of LPA and its receptor subtypes involved in biological actions.